Skip to main content

Table 5 Exacerbations outcomes in tiotropium and placebo groups according to different threshold criteria for bronchodilator responsiveness.

From: Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial

  Tiotropium Placebo Hazard (or Rate) Ratio (95%CI) (tiotropium/placebo) p-value
Patients with ≥1 exacerbation, n (%)
Responsiveness Criterion A     
   Nonresponder 913 (67.3) 946 (67.9) 0.86 (0.79, 0.94) 0.0014
   Responder 1021 (67.2) 1036 (68.5) 0.86 (0.79, 0.94) 0.0008
Responsiveness Criterion B     
   Nonresponder 634 (63.7) 676 (67.6) 0.85 (0.76, 0.95) 0.0029
   Responder 1300 (69.1) 1306 (68.5) 0.87 (0.80, 0.94) 0.0003
Responsiveness Criterion C     
   Nonresponder 1198 (67.7) 1204 (67.5) 0.89 (0.82, 0.96) 0.0036
   Responder 736 (66.4) 778 (69.3) 0.82 (0.74, 0.91) 0.0002
Number of exacerbations/patient year, mean
Responsiveness Criterion A     
   Nonresponder 0.76 0.87 0.87 (0.79, 0.95) 0.0019
   Responder 0.69 0.82 0.85 (0.78, 0.92) 0.0002
Responsiveness Criterion B     
   Nonresponder 0.65 0.77 0.84 (0.75, 0.94) 0.0026
   Responder 0.76 0.88 0.86 (0.80, 0.93) 0.0001
Responsiveness Criterion C     
   Nonresponder 0.74 0.86 0.86 (0.79, 0.93) 0.0001
   Responder 0.70 0.81 0.86 (0.77, 0.95) 0.0025
  1. p-value and hazard ratio based on Cox-regression for analysis of time to first exacerbation. p-value and rate ratio based on Poisson-regression with adjustment for overdispersion for analysis of number of exacerbations per patient year.
\